References
- Aggarwal S, Parveen F, Faridi RM, et al (2011). Vascular endothelial growth factor gene polymorphisms in North Indian patients with recurrent miscarriages. Reprod Biomed Online, 22, 59-64. https://doi.org/10.1016/j.rbmo.2010.08.005
- Ben-Ari Z, Tambur AR, Pappo O, et al (2006). Platelet-derived growth factor gene polymorphism in recurrent hepatitis C infection after liver transplantati don. Transplantat, 81, 392-7. https://doi.org/10.1097/01.tp.0000173645.89064.c7
- Bravo M, Vasquez R, Rubio H, et al (1991). Production of platelet-derived growth factor by human lung cancer. Respir Med, 85, 479-85. https://doi.org/10.1016/S0954-6111(06)80265-9
- Cao Y (2005). Opinion: emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis. Nat Rev Cancer, 5, 735-43. https://doi.org/10.1038/nrc1693
- Chung CK, Antoniades HN (1992). Expression of c-sis/platelet-derived growth factor B, insulin-like growth factor I, and transforming growth factor alpha messenger RNAs and their respective receptor messenger RNAs in primary human gastric carcinomas: in vivo studies with in situ hybridization and immunocytochemistry. Cancer Res, 52, 3453-9.
- Donnem T, Al-Saad S, Al-Shibli K, Busund LT, Bremnes RM (2010). Co-expression of PDGFB and VEGFR-3 strongly correlates with lymph node metastasis and poor survival in non-small-cell lung cancer. Ann Oncol, 21, 223-31. https://doi.org/10.1093/annonc/mdp296
- Hahn LW, Ritchie MD, Moore JH (2003). Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. Bioinformatics, 19, 376-82. https://doi.org/10.1093/bioinformatics/btf869
- Hamdani NH, Qadri SK, Aggarwalla R, et al (2012). Clinicopathological study of gall bladder carcinoma with special reference to gallstones: our 8-year experience from Eastern India. Asian Pac J Cancer Prev, 13, 5613-7. https://doi.org/10.7314/APJCP.2012.13.11.5613
- Hsing AW, Gao YT, Han TQ, et al (2007). Gallstones and the risk of biliary tract cancer: a population-based study. Br J Cancer, 97, 1577-82. https://doi.org/10.1038/sj.bjc.6604047
- Kara O, Duman BB, Kara B, et al (2012). Analysis of PTEN, VEGF, HER2 and P53 status in determining colorectal cancerbenefit from bevacizumab therapy. Asian Pac J Cancer Prev, 13, 6397-401. https://doi.org/10.7314/APJCP.2012.13.12.6397
- Karaca H, Deniz K, Berk V, Inanc M, Ozkan M (2012). Association of human epidermal growth factor receptor-2 expression and clinicopathological findings in patients with colorectal cancer. Asian Pac J Cancer Prev, 13, 6221-5. https://doi.org/10.7314/APJCP.2012.13.12.6221
- Kumari N, Kapoor VK, Krishnani N, Kumar K, Baitha DK (2012). Role of C-erbB2 expression in gallbladder cancer. Indian J Pathol Microbiol, 55, 75-9. https://doi.org/10.4103/0377-4929.94862
- Kuraoka K, Matsumura S, Hamai Y, et al (2003). A single nucleotide polymorphism in the transmembrane domain coding region of HER2 is associated with development and malignant phenotype of gastric cancer. Int J Cancer, 107, 593-6. https://doi.org/10.1002/ijc.11450
- Li M, Zhang Z, Li X, et al (2014). Whole exome and targeted gene sequencing of gall bladder carcinoma identifies recurrent mutations in the ErBb pathway. Nature Genetics, 46, 872-6. https://doi.org/10.1038/ng.3030
- Marmor MD, Skaria KB, Yarden Y (2004). Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys, 58, 903-13. https://doi.org/10.1016/j.ijrobp.2003.06.002
- Matsumoto S, Yamada Y, Narikiyo M, et al (2007). Prognostic significance of platelet-derived growth factor-BB expression in human esophageal squamous cell carcinomas. Anticancer Res, 27, 2409-14.
- McKay JA, Loane JF, Ross VG, et al (2002). C-erbB-2 is not a major factor in the development of colorectal cancer. Br J Cancer, 86, 568-73. https://doi.org/10.1038/sj.bjc.6600127
- Mishra K, Behari A, Kapoor VK, et al (2013). Vascular endothelial growth factor single nucleotide polymorphism in gall bladder cancer. J Gastroenterol Hepatol, 28, 1678-85.
- Muddana V, Park J, Lamb J, et al (2010). Are genetic variants in the platelet-derived growth factor [beta] gene associated with chronic pancreatitis? Pancreas, 39, 1215-9. https://doi.org/10.1097/MPA.0b013e3181e2d4a0
- Nakajima M, Sawada H, Yamada Y, et al (1999). The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer, 85, 1894-902. https://doi.org/10.1002/(SICI)1097-0142(19990501)85:9<1894::AID-CNCR3>3.0.CO;2-J
- Nakazawa K, Dobashi Y, Suzuki S, et al (2005). Amplification and overexpression of c-erbB-2, epidermal growth factor receptor and c-met in biliary tract cancers. J Pathol, 206, 356-65. https://doi.org/10.1002/path.1779
- National Cancer Registry Programme (2002). Two-year report of the Population Based Cancer Registries, 1997-98. New Delhi: Indian Council of medical research.
- Panagiotou I, Georgiannos SN, Tsiambas E, et al (2012). Impact of HER2 and PTEN simultaneous deregulation in non-small cell lung carcinoma: correlation with biological behavior. Asian Pac J Cancer Prev, 13, 6311-8. https://doi.org/10.7314/APJCP.2012.13.12.6311
- Papewalis J, Nikitin AYu, Rajewsky MF (1991). G to A polymorphism at amino acid codon 655 of the human erbB-2/ HER2gene. Nucleic Acids Res, 19, 5452.
- Prakash S, Prasad N, Sharma RK, Faridi RM, Agrawal S (2012). Vascular endothelial growth factor gene polymorphisms in North Indian patients with end stage renal disease. Cytokine, 58, 261-6. https://doi.org/10.1016/j.cyto.2012.01.020
- Qu K, Liu SN, Chang HL, et al (2012). Gallbladder cancer: a subtype of biliary tract cancer which is a current challenge in China. Asian Pac J Cancer Prev, 13, 1317-20. https://doi.org/10.7314/APJCP.2012.13.4.1317
- Quaye L, Song H, Ramus SJ, et al (2009). Tagging singlenucleotide polymorphisms in candidate oncogenes and susceptibility to ovarian cancer. Br J Cancer, 100, 993-1001. https://doi.org/10.1038/sj.bjc.6604947
- Rakhshani N, Kalantari E, Bakhti H, Sohrabi MR, Mehrazma M (2014). Evaluation of HER-2/neu overexpression in gastric carcinoma using a tissue microarray. Asian Pac J Cancer Prev, 15, 7597-602. https://doi.org/10.7314/APJCP.2014.15.18.7597
- Randi G, Franceschi S, La Vecchia C (2006). Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer, 118, 1591-602. https://doi.org/10.1002/ijc.21683
- Sole X, Guino E, Valls J, Iniesta R, Moreno V (2006). SNPStats: a web tool for the analysis of association studies. Bioinformatics, 22, 1928-9. https://doi.org/10.1093/bioinformatics/btl268
- Wang L, Habuchi T, Takahashi T, et al (2002). No association between HER2 gene polymorphism at codon 655and a risk of bladder cancer. Int J Cancer, 97, 787-90. https://doi.org/10.1002/ijc.10129
- Warde-Farley D, Donaldson SL, Comes O, et al (2010). The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res, 38, 214-20. https://doi.org/10.1093/nar/gkq537
- Wong FH, Hu CP, Chiu JH, et al (1994). Expression of multiple oncogenes in human esophageal carcinomas. Cancer Invest, 12, 121-31. https://doi.org/10.3109/07357909409024867
- Xie D, Shu XO, Deng Z, et al (2000). Population-based, casecontrol study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst, 92, 412-7. https://doi.org/10.1093/jnci/92.5.412
- Yamamoto Y, Yamagishi S, Hsu CC, Yamamoto H (1996). Advanced glycation end products-receptor interactions stimulate the growth of human pancreatic cancer cells through the induction of platelet-derived growth factor-B. Biochem Biophys Res Commun, 222, 700-5. https://doi.org/10.1006/bbrc.1996.0807
- Zahir ST, Tafti HF, Rahmani K (2014). Overexpression of HER- 2/neu in patients with prostatic adenocarcinoma. Asian Pac J Cancer Prev, 15, 6425-8. https://doi.org/10.7314/APJCP.2014.15.15.6425
Cited by
- Randomized-Control Screening Trials to Lower Gall Bladder Cancer Mortality in High Risk Populations vol.17, pp.4, 2016, https://doi.org/10.7314/APJCP.2016.17.4.2325
- Association of HER2 codon 655 polymorphism with ovarian cancer vol.37, pp.6, 2016, https://doi.org/10.1007/s13277-015-4609-2